Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 5/20 | 0.58 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.57 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | IL18 | Q14116 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9223532 | 0.93 | POLB (0.64) | RORCPOLBSAE1UBA2MAPT | |
| SCHEMBL15899425 | 0.90 | POLB (0.59) | RORCPOLBSAE1UBA2MAPT | |
| SCHEMBL7473435 | 0.90 | POLB (0.53) | RORCPOLBSAE1UBA2MAPT | |
| SCHEMBL7308833 | 0.89 | L3MBTL1 (0.58) | RORCPOLBMAPTHTTPGR | |
| SCHEMBL23054844 | 0.89 | POLB (0.58) | RORCPOLBSAE1UBA2MAPT | |
| SCHEMBL13716356 | 0.89 | RORC (0.53) | RORCPOLBSAE1UBA2MAPT | |
| SCHEMBL15480399 | 0.89 | HDAC1 (0.65) | RORCKDM4EPAX8 | |
| SCHEMBL8638627 | 0.87 | RORC (0.52) | RORCPOLBSAE1UBA2MAPT | |
| SCHEMBL20777973 | 0.87 | PGR (0.65) | RORCPOLBLMNAHTTPGR | |
| SCHEMBL15480393 | 0.87 | PGR (0.65) | RORCPOLBLMNAHTTPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267702-A1 | Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis | HUANG TIEN L | 2010-10-21 | — | — | US | disclosed |
| US-20100267702-A1 | Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis | HUANG TIEN L | 2010-10-21 | — | — | US | disclosed |
| WO-2008070831-A2 | BISBENZAMIDINES AND BISBENZAMIDOXIMES FOR THE TREATMENT OF HUMAN AFRICAN TRYPANOSOMIASIS | XAVIER UNIVERSITY OF LOUISIANA (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070831-A2 | BISBENZAMIDINES AND BISBENZAMIDOXIMES FOR THE TREATMENT OF HUMAN AFRICAN TRYPANOSOMIASIS | XAVIER UNIVERSITY OF LOUISIANA (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139534-A1 | or sleeping sickness, caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense; lethargy, continous sleep, breakdown of neurological function, coma and death; viricide, antiprotozoa agent; Pentamidine analog; topoisomerases II inhibitor; inhibit synthesis of DNA, RNA by parasites | XAVIER UNIVERSITY OF LOUISIANA (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139534-A1 | or sleeping sickness, caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense; lethargy, continous sleep, breakdown of neurological function, coma and death; viricide, antiprotozoa agent; Pentamidine analog; topoisomerases II inhibitor; inhibit synthesis of DNA, RNA by parasites | XAVIER UNIVERSITY OF LOUISIANA (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139534-A1 | or sleeping sickness, caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense; lethargy, continous sleep, breakdown of neurological function, coma and death; viricide, antiprotozoa agent; Pentamidine analog; topoisomerases II inhibitor; inhibit synthesis of DNA, RNA by parasites | TOP2A, TOP2B, TOP1 | RORC 4140/4885POLB 4/4885SAE1 909/4885 |
| US-20100267702-A1 | Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis | PBRM1, TFB2M, ABAT | RORC 4280/4885POLB 344/4885SAE1 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.